#bpdcnday #rarecancer #cancerawareness #bpdcn #cpe | Cancer Patients Europe - CPE 💡 BPDCN Awareness Day Rare doesn’t mean invisible. On #BPDCNDay, we raise awareness of BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm is an extremely rare and aggressive blood cancer) and stan...

📢Rare doesn’t mean invisible.

On #BPDCNDay, we raise awareness of #BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) and stand with the community calling for earlier diagnosis and better care.

➡️Learn more: lnkd.in/eSRCq8nM

🔗Watch our video: www.linkedin.com/feed/update/...

Tagraxofusp, azacitidine, and venetoclax triplet shows efficacy Tagraxofusp, azacitidine, and venetoclax triplet shows efficacy in phase 2 trial updates at ASH in Orlando, Florida.

Triplet therapy shows efficacy, tolerability, and transplant potential in #BPDCN

sohoinsider.com/meetings-con...

🧬 #CARLA annonce que #CARLA001 entre en clinique, une thérapie #CAR_T pionnière anti #CD123

Ce programme est conçu pour répondre à un besoin non satisfait chez les patients atteints de #Leucémie myéloïde aiguë #LMA R/R et de #Néoplasmie dendritique plasmacytoïde blastoïde #BPDCN

Menarini Group Unveils New Insights on ELZONRIS® at ASH Annual Meeting Menarini Group announces significant new findings on ELZONRIS® at the upcoming ASH Annual Meeting, aiding patients with BPDCN.

Menarini Group Unveils New Insights on ELZONRIS® at ASH Annual Meeting #Italy #Menarini #Florence #BPDCN #ELZONRIS

Menarini Group Presents New Data on ELZONRIS at ASH 2025 Annual Meeting Menarini Group and Stemline Therapeutics reveal new findings regarding ELZONRIS® data at the 67th ASH Annual Meeting, highlighting innovative treatments for BPDCN.

Menarini Group Presents New Data on ELZONRIS at ASH 2025 Annual Meeting #USA #Orlando #Menarini_Group #BPDCN #ELZONRIS

Menarini Group Unveils New Insights on ELZONRIS at ASH 2025 Annual Meeting Menarini Group and Stemline Therapeutics will present essential findings on ELZONRIS at ASH's Annual Meeting, emphasizing its potential in treating aggressive blood cancers.

Menarini Group Unveils New Insights on ELZONRIS at ASH 2025 Annual Meeting #USA #Orlando #Menarini #BPDCN #ELZONRIS

Menarini Group Unveils Promising Data for ELZONRIS® at ASH Annual Meeting Menarini Group announces significant results for ELZONRIS® at the upcoming ASH Annual Meeting, highlighting new treatment options for patients with BPDCN.

Menarini Group Unveils Promising Data for ELZONRIS® at ASH Annual Meeting #USA #Orlando #Menarini_Group #BPDCN #ELZONRIS

Menarini Group Unveils Promising Findings on ELZONRIS for BPDCN at ASH Meeting Key new findings on ELZONRIS treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) to be showcased at the 67th American Society of Hematology Annual Meeting in December 2025.

Menarini Group Unveils Promising Findings on ELZONRIS for BPDCN at ASH Meeting #Italy #Florence #Menarini_Group #BPDCN #ELZONRIS

AbbVie Seeks FDA's Green Light for Pivekimab Sunirine in BPDCN Treatment AbbVie has submitted a Biologics License Application for Pivekimab sunirine, aimed at treating patients with the rare blood cancer BPDCN, providing hope where treatment options are limited.

AbbVie Seeks FDA's Green Light for Pivekimab Sunirine in BPDCN Treatment #United_States #AbbVie #North_Chicago #BPDCN #Pivekimab_Sunirine

Nico Gagelmann: Highlights from EHA 2025 - Breakthroughs in ET, Myelofibrosis, MM, MDS, and BPDCN - OncoDaily Nico Gagelmann: Highlights from EHA 2025 - Breakthroughs in ET, Myelofibrosis, MM, MDS, and BPDCN / BPDCN, cancer, CAR-T, EHA 2025, Essential thrombocythemia,

Highlights from EHA 2025: Breakthroughs in ET, Myelofibrosis, MM, MDS, and BPDCN - Nico Gagelmann
@nicogagelmann.bsky.social

oncodaily.com/insight/eha-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA2025 #ET #Myelofibrosis #MM #Myeloma #MDS #BPDCN

🎥 Watch our interview from #ASCO25 with the fantastic Naveen Pemmaraju of @mdanderson.bsky.social‬, who presents the updated results of the CADENZA study exploring the safety & efficacy of pivekimab sunirine in #BPDCN.

Click here:
👉 buff.ly/goc03Bc

#RareDisease #TrialUpdate #CTSM #BloodSky #HemOnc

Menarini Group Partners with VisualDx to Enhance BPDCN Diagnosis with AI Tools Menarini Group teams up with VisualDx to advance the diagnosis of BPDCN through innovative AI-driven methods, reshaping treatment paths for patients.

Menarini Group Partners with VisualDx to Enhance BPDCN Diagnosis with AI Tools #Italy #Florence #Menarini_Group #VisualDx #BPDCN

Menarini and VisualDx Collaborate to Aid in Early Detection of BPDCN Menarini and VisualDx join forces to enhance early identification of blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematological malignancy.

Menarini and VisualDx Collaborate to Aid in Early Detection of BPDCN #Italy #Menarini #Florence #VisualDx #BPDCN

Menarini Group Teams Up with VisualDx to Improve BPDCN Diagnosis and Early Detection Menarini Group and VisualDx collaborate to enhance the identification of those possibly affected by BPDCN, utilizing advanced AI technology for effective diagnosis.

Menarini Group Teams Up with VisualDx to Improve BPDCN Diagnosis and Early Detection #Italy #Florence #Menarini_Group #VisualDx #BPDCN

Menarini Group and VisualDx Join Forces to Enhance BPDCN Detection with AI Technology The Menarini Group collaborates with VisualDx to improve identification of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) using AI tools, enhancing early diagnosis.

Menarini Group and VisualDx Join Forces to Enhance BPDCN Detection with AI Technology #Italy #Florence #Menarini_Group #VisualDx #BPDCN

Menarini and VisualDx Join Forces to Enhance BPDCN Diagnosis with AI Technology Menarini Group partners with VisualDx to enhance early detection of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) using AI. This collaboration aims to improve patient outcomes through innovative medical technologies.

Menarini and VisualDx Join Forces to Enhance BPDCN Diagnosis with AI Technology #Italy #Florence #Menarini_Group #VisualDx #BPDCN

Today is #BPDCNday!🩸

Join us in raising awareness & watch our interview with the #BPDCN expert himself, Dr Naveen Pemmaraju, to hear about major breakthroughs that have the potential to improve the outcomes of patients with this #RareDisease:

🎥 https://buff.ly/3Wfy8e8

#HemOnc #Leusm #BloodSky

Article of the Week, Suggested by the BPDCN International Registry - OncoDaily Article of the Week, Suggested by the BPDCN International Registry / Astghik Voskanyan, Blastic Plasmacytoid Dendritic Cell Neoplasm, BPDCN, BPDCN

Article of the Week, Suggested by the BPDCN International Registry
@ash-hematology.bsky.social

oncodaily.com/science/bpdc...

#BPDCN #BPDCNInternationalRegistry #Cancer #Oncology #HematologicMalignancy #IMMONC #Medicine #Health #ImmuneOncologyResearchInstitute #OncoDaily

Check out our new podcast!🎙️

Featuring Naveen Pemmaraju who takes a deep dive into #BPDCN. He discusses current therapies, the role of tagraxofusp, and emerging novel agents!

🎧Listen here: https://buff.ly/41ErHEU

#RareDiseases #HemOnc #ImmunoOnc

New insights in #AML and #BPDCN care with Shai Shimony @danafarber.bsky.social at #ASH24 🎥

⭐AML-MR mutations drive CPX-351's benefit over 7+3
⭐Machine learning identifies a 3-parameter survival model for BPDCN
⭐Social determinants of health impact survival in AML across ELN risk groups

Here are the top line overall survival (OS) data with the new #BPDCN 3-parameter prognostic model by Shai Shimony from our BPDCN Center: Favorable, 100% 2-year OS; intermediate, 39% OS and median 21.1 months; adverse, 5% OS and median 9.9 months (factors: age, marrow involvement, signaling mut)

Come see a session about clinical outcomes in #BPDCN, including a machine learning model that has generated a clinically useful and simple 3 factor prognostic scoring model for survival in the disease by superstar new faculty member Shai Shimony @danafarber.bsky.social

How I Treat #BPDCN
@ash-hematology.bsky.social @mkd-bmt.bsky.social #ASH24 #leusm

ashpublications.org/blood/articl...

Hey @nitinjainmd.bsky.social, gotta get Dr Pemmaraju of #BPDCN fame on 🦋 so we can maintain our triple “N” threat here 🙏